July is Sarcoma Awareness Month and according to Cleveland Clinic, sarcoma accounts for about 1 percent of adult cancers but 15 percent to 20 percent of childhood cancers. The Black community speaks ...

Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.

Summit Therapeutics has released more Phase III trial data for ivonescimab in non-small cell lung cancer (NSCLC) as it awaits ...

A new drug is doubling survival time for pancreatic cancer patients. Daraxonrasib, the drug being taken by former Sen. Ben ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...

Menarini Asia-Pacific today announced an exclusive partnership with Pharmacosmos A/S to register, commercialise and ...

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, ...

Anktiva shows strong NMIBC results and pipeline upside, but valuation, dilution and cash burn raise risk—read now.

Continued low early termination rate (4.5%) among the first 200 patients enrolled in the study suggests Halneuron® and placebo treatment have been well tolerated - ...

Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the combination of pembrolizumab and enfortumab vedotin for use both before ...

Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers.